scholarly journals PGI14 HOSPITAL LENGTH OF STAY FOR PATIENTS DIAGNOSED WITH C. DIFFICILE INFECTION LINKED TO DIAGNOSTIC TEST METHOD – – REAL WORLD EVIDENCE FROM U.S.

2019 ◽  
Vol 22 ◽  
pp. S180 ◽  
Author(s):  
J. Engstrom-Melnyk ◽  
C. Liu ◽  
Y.C. Lee ◽  
M. Brackney ◽  
C. Newhouse
2020 ◽  
Vol 27 (1) ◽  
pp. e100109 ◽  
Author(s):  
Hoyt Burdick ◽  
Eduardo Pino ◽  
Denise Gabel-Comeau ◽  
Andrea McCoy ◽  
Carol Gu ◽  
...  

BackgroundSevere sepsis and septic shock are among the leading causes of death in the USA. While early prediction of severe sepsis can reduce adverse patient outcomes, sepsis remains one of the most expensive conditions to diagnose and treat.ObjectiveThe purpose of this study was to evaluate the effect of a machine learning algorithm for severe sepsis prediction on in-hospital mortality, hospital length of stay and 30-day readmission.DesignProspective clinical outcomes evaluation.SettingEvaluation was performed on a multiyear, multicentre clinical data set of real-world data containing 75 147 patient encounters from nine hospitals across the continental USA, ranging from community hospitals to large academic medical centres.ParticipantsAnalyses were performed for 17 758 adult patients who met two or more systemic inflammatory response syndrome criteria at any point during their stay (‘sepsis-related’ patients).InterventionsMachine learning algorithm for severe sepsis prediction.Outcome measuresIn-hospital mortality, length of stay and 30-day readmission rates.ResultsHospitals saw an average 39.5% reduction of in-hospital mortality, a 32.3% reduction in hospital length of stay and a 22.7% reduction in 30-day readmission rate for sepsis-related patient stays when using the machine learning algorithm in clinical outcomes analysis.ConclusionsReductions of in-hospital mortality, hospital length of stay and 30-day readmissions were observed in real-world clinical use of the machine learning-based algorithm. The predictive algorithm may be successfully used to improve sepsis-related outcomes in live clinical settings.Trial registration numberNCT03960203


2018 ◽  
Author(s):  
Hoyt Burdick ◽  
Eduardo Pino ◽  
Denise Gabel-Comeau ◽  
Andrea McCoy ◽  
Carol Gu ◽  
...  

AbstractObjectiveTo validate performance of a machine learning algorithm for severe sepsis determination up to 48 hours before onset, and to evaluate the effect of the algorithm on in-hospital mortality, hospital length of stay, and 30-day readmission.SettingThis cohort study includes a combined retrospective analysis and clinical outcomes evaluation: a dataset containing 510,497 patient encounters from 461 United States health centers for retrospective analysis, and a multiyear, multicenter clinical data set of real-world data containing 75,147 patient encounters from nine hospitals for clinical outcomes evaluation.ParticipantsFor retrospective analysis, 270,438 adult patients with at least one documented measurement of five out of six vital sign measurements were included. For clinical outcomes analysis, 17,758 adult patients who met two or more Systemic Inflammatory Response Syndrome (SIRS) criteria at any point during their stay were included.ResultsAt severe sepsis onset, the MLA demonstrated an AUROC of 0.91 (95% CI 0.90, 0.92), which exceeded those of MEWS (0.71, P<001), SOFA (0.74; P<.001), and SIRS (0.62; P<.001). For severe sepsis prediction 48 hours in advance of onset, the MLA achieved an AUROC of 0.77 (95% CI 0.73, 0.80). For the clinical outcomes study, when using the MLA, hospitals saw an average 39.5% reduction of in-hospital mortality, a 32.3% reduction in hospital length of stay, and a 22.7% reduction in 30-day readmission rate.ConclusionsThe MLA accurately predicts severe sepsis onset up to 48 hours in advance using only readily available vital signs in retrospective validation. Reductions of in-hospital mortality, hospital length of stay, and 30-day readmissions were observed in real-world clinical use of the MLA. Results suggest this system may improve severe sepsis detection and patient outcomes over the use of rules-based sepsis detection systems.KEY POINTSQuestionIs a machine learning algorithm capable of accurate severe sepsis prediction, and does its clinical implementation improve patient mortality rates, hospital length of stay, and 30-day readmission rates?FindingsIn a retrospective analysis that included datasets containing a total of 585,644 patient encounters from 461 hospitals, the machine learning algorithm demonstrated an AUROC of 0.93 at time of severe sepsis onset, which exceeded those of MEWS (0.71), SOFA (0.74), and SIRS (0.62); and an AUROC of 0.77 for severe sepsis prediction 48 hours in advance of onset. In an analysis of real-world data from nine hospitals across 75,147 patient encounters, use of the machine learning algorithm was associated with a 39.5% reduction in in-hospital mortality, a 32.3% reduction in hospital length of stay, and a 22.7% reduction in 30-day readmission rate.MeaningThe accurate and predictive nature of this algorithm may encourage early recognition of patients trending toward severe sepsis, and therefore improve sepsis related outcomes.STRENGTHS AND LIMITATIONS OF THIS STUDYA retrospective study of machine learning severe sepsis prediction from a dataset with 510,497 patient encounters demonstrates high accuracy up to 48 hours prior to onset.A multicenter clinical study of real-world data using this machine learning algorithm for severe sepsis alerts achieved reductions of in-hospital mortality, length of stay, and 30-day readmissions.The required presence of an ICD-9 code to classify a patient as severely septic in our retrospective analysis potentially limits our ability to accurately classify all patients.Only adults in US hospitals were included in this study.For the real-world section of the study, we cannot eliminate the possibility that implementation of a sepsis algorithm raised general awareness of sepsis within a hospital, which may lead to higher recognition of septic patients, independent of algorithm performance.


2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S17-S17
Author(s):  
Thomas Walsh ◽  
Briana DiSilvio ◽  
Crystal Hammer ◽  
Moeezullah Beg ◽  
Swati Vishwanathan ◽  
...  

Abstract Background Community-acquired pneumonia and healthcare-associated pneumonia are often treated with prolonged antibiotic therapy. Procalcitonin (PCT) has effectively and safely reduced antibiotic use for pneumonia in controlled studies. However, limited data exist regarding PCT guidance in real-world settings for management of pneumonia. Methods A retrospective, preintervention/postintervention quality improvement study was conducted to compare management for patients admitted with pneumonia before and after implementation of PCT guidance at two teaching hospitals in Pittsburgh, Pennsylvania. The preintervention period was March 1, 2014 through October 31, 2014, and the post-intervention period was March, 1 2015 through October 31, 2015. Results A total of 152 and 232 patients were included in the preintervention and postintervention cohorts, respectively. When compared with the preintervention group, the mean duration of therapy decreased (9.9 vs. 6.1 days; P &lt; 0.001). More patients received an appropriate duration of 7 days or less (26.9% vs. 66.4%; P &lt; 0.001). Additionally, mean hospital length of stay decreased in the postintervention group (4.9 vs. 3.5 days; P = 0.006). Pneumonia-related 30-day readmission rates (7.2% vs. 4.3%; P = 0.99) were unaffected. In the postintervention group, patients with PCT levels &lt; 0.25 µg/l received shorter mean duration of therapy compared with patients with levels &gt;0.25 µg/l (8.0 vs. 4.6 days; P &lt; 0.001) as well as reduced hospital length of stay (3.9 vs. 3.2 days; P = 0.02). Conclusion In this real-world practice study, PCT guidance led to shorter durations of total antibiotic therapy and abridged inpatient length of stay without affecting hospital re-admissions. Disclosures All authors: No reported disclosures.


2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S98-S98
Author(s):  
Corey J Medler ◽  
Mary Whitney ◽  
Juan Galvan-Cruz ◽  
Ron Kendall ◽  
Rachel Kenney ◽  
...  

Abstract Background Unnecessary and prolonged IV vancomycin exposure increases risk of adverse drug events, notably nephrotoxicity, which may result in prolonged hospital length of stay. The purpose of this study is to identify areas of improvement in antimicrobial stewardship for vancomycin appropriateness by clinical pharmacists at the time of therapeutic drug monitoring (TDM). Methods Retrospective, observational cohort study at an academic medical center and a community hospital. Inclusion: patient over 18 years, received at least three days of IV vancomycin where the clinical pharmacy TDM service assessed for appropriate continuation for hospital admission between June 19, 2019 and June 30, 2019. Exclusion: vancomycin prophylaxis or administered by routes other than IV. Primary outcome was to determine the frequency and clinical components of inappropriate vancomycin continuation at the time of TDM. Inappropriate vancomycin continuation was defined as cultures positive for methicillin-susceptible Staphylococcus aureus (MRSA), vancomycin-resistant bacteria, and non-purulent skin and soft tissue infection (SSTI) in the absence of vasopressors. Data was reported using descriptive statistics and measures of central tendency. Results 167 patients met inclusion criteria with 38.3% from the ICU. SSTIs were most common indication 39 (23.4%) cases, followed by pneumonia and blood with 34 (20.4%) cases each. At time of vancomycin TDM assessment, vancomycin continuation was appropriate 59.3% of the time. Mean of 4.22 ± 2.69 days of appropriate vancomycin use, 2.18 ± 2.47 days of inappropriate use, and total duration 5.42 ± 2.94. 16.4% patients developed an AKI. Majority of missed opportunities were attributed to non-purulent SSTI (28.2%) and missed MRSA nares swabs in 21% pneumonia cases (table 1). Conclusion Vancomycin is used extensively for empiric treatment of presumed infections. Appropriate de-escalation of vancomycin therapy is important to decrease the incidence of adverse effects, decreasing hospital length of stay, and reduce development of resistance. According to the mean duration of inappropriate therapy, there are opportunities for pharmacy and antibiotic stewardship involvement at the time of TDM to optimize patient care (table 1). Missed opportunities for vancomycin de-escalation Disclosures All Authors: No reported disclosures


Sign in / Sign up

Export Citation Format

Share Document